bioAffinity Technologies Past Earnings Performance
Past criteria checks 0/6
bioAffinity Technologies's earnings have been declining at an average annual rate of -9.1%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 140.9% per year.
Key information
-9.1%
Earnings growth rate
33.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 140.9% |
| Return on equity | -270.6% |
| Net Margin | -90.2% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How bioAffinity Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 9 | -8 | 9 | 2 |
| 30 Jun 24 | 7 | -9 | 9 | 2 |
| 31 Mar 24 | 5 | -8 | 8 | 2 |
| 31 Dec 23 | 3 | -8 | 7 | 2 |
| 30 Sep 23 | 0 | -7 | 6 | 2 |
| 30 Jun 23 | 0 | -10 | 4 | 2 |
| 31 Mar 23 | 0 | -8 | 3 | 2 |
| 31 Dec 22 | 0 | -8 | 2 | 2 |
| 30 Sep 22 | 0 | -12 | 2 | 1 |
| 30 Jun 22 | 0 | -9 | 1 | 1 |
| 31 Mar 22 | 0 | -7 | 1 | 1 |
| 31 Dec 21 | 0 | -6 | 1 | 1 |
| 30 Sep 21 | 0 | -3 | 1 | 1 |
Quality Earnings: BIAF is currently unprofitable.
Growing Profit Margin: BIAF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIAF is unprofitable, and losses have increased over the past 5 years at a rate of 9.1% per year.
Accelerating Growth: Unable to compare BIAF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIAF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BIAF has a negative Return on Equity (-270.62%), as it is currently unprofitable.